REaCT-HOLD BMA, “A randomised trial comparing continuation or de-escalation of bone modifying agents (BMA) in patients treated for over 2 years for bone metastases from either breast or castration-resistant prostate cancer” was selected to be discussed at the GRASP San Antonio Breast Cancer Symposium (SABCS) 2021 Poster Walkthroughs.

GRASP, which stands for Guiding Researchers and Advocate to Scientific Partnerships, is a patient-led organization that brings together patients, clinicians, and researchers to exchange ideas and learn from each other in order to accelerate scientific breakthroughs. REaCT-HOLD BMA was one of 74 posters selected, among several thousand that were presented at SABCS 2021.

These posters were selected for their potential to advance cancer research, and ultimately help people living with cancer live longer and better lives. For this reason, REaCT-HOLD BMA was awarded with the “GRASP Choice Award.”

About REaCT

REthinking Clinical Trials (REaCT) is a unique research program aimed at improving the lives of people with cancer through patient-centred, pragmatic clinical trials. Based at The Ottawa Hospital, the REaCT program engages patients and their loved ones in research every step of the way, from generating ideas to setting priorities to designing studies and sharing results. Unlike most cancer clinical trials, which are focused on evaluating experimental treatments in a very narrow patient population, REaCT trials compare standard approved treatments in a real-world setting with a broad range of patients. In this way, REaCT trials can efficiently answer some of the most important questions for cancer patients and the health care system.